Mifepristone Filing Supports 2023 US FDA Actions, But Experts Caution Against Overanalyzing

 
• By Sarah Karlin-Smith

Filing in the Whole Women’s Health mifepristone case defends the FDA’s 2023 decision on the abortion pill safety program, but experts warn it does not necessarily signal the Trump Administration position in other mifepristone cases attempting to restrict medication abortion access.

box of mifepristone tables on blue background
Filings in key mifepristone cases are being closely watched for signals that the Trump Justice Department will take a different approach than the Biden Administration. (Shutterstock)
Key Takeaways
  • The first significant legal filing in mifepristone litigation under the Trump Administration defends the FDA’s 2023 decision on its safety program.
  • The brief is notable because it does not contain any antiabortion language or arguments typically associated with the Republican party.
  • Experts cautioned that it is unclear whether the brief indicates the Trump Administration’s overall strategy on the abortion pill, including whether it will continue fighting legal cases seeking to reinstate stricter safety measures for the drug.

The Trump Administration’s first significant legal filing in mifepristone litigation defends the US Food and Drug Administration’s 2023 decision on the abortion medication’s Risk Evaluation...

But the brief, in a case arguing the FDA should remove the entire mifepristone REMS, perhaps is most notable for what it lacks, which is any direct argument pushing for...

More from Litigation

More from Legal & IP